

LITERATÚRA

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Dostupné na: www.ginasthma.org
2. The European Lung White Book. Respiratory health and disease in Europe. ISBN 978-1-84984-042-2
3. Národné centrum zdravotníckych informácií. Zdravotnícka ročenka Slovenskej republiky 2018. ISBN 978-80-89292-71-4
4. Meilinger M, Horváth I, Laššán Š, et al. Asthma control and perception from patient perspective in the Central European region. The ASCERTAIN survey. Pneumo Update Europe Poster. 9–10 June 2017, Vienna.
5. O'Byrne P, Fabbri LM, Pavord ID, et al. Asthma progression and mortality: the role of inhaled corticosteroids. *Eur Respir J* 2019; 54: 1900491.
6. Kuruville ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes and mechanisms of disease. *Clin rev Allergy Immunol* 2019; 56(2): 219–233.
7. Ozdemir C, Kucuksezer UC, Akdis M, et al. The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies. *Expert Rev Respir Med* 2018; 12(9): 733–743.
8. Papi A, Brightling C, Pedersen SE, et al. Asthma. *Lancet* 2018; 391: 783–800.
9. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J* 2020; 55: 1900588.
10. Laššán Š, Téglás I, Laššánová M. Targeting asthma control in real-life clinical practice by using ICS/LABA combination. *Klin Farmakol Farm* 2018; 33(3): 21–27.
11. Muneswarao J, Hassali MA, Ibrahim B, et al. It is time to change the way we manage mild asthma: an update in GINA 2019. *Respir Res* 2019; 20: 183.
12. Barnes PJ, Szefler SJ, Reddel HK, et al. Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. *J Allergy Clin Immunol* 2019; 144: 1180–1186.
13. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018. Dostupné na: www.ginasthma.org
14. Global Initiative for Asthma. Difficult-to-treat & Severe Asthma in adolescent and adult patients. Diagnosis and management. V2.0 April 2019. Dostupné na: www.ginasthma.org
15. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. *N Engl J Med* 2007; 356: 2040–2052.
16. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of Physician-, Biomarker-, and Symptom- Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults with Asthma. The BASALT Randomized Controlled Trial. *JAMA* 2012; 308(10): 987–997.
17. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. *Lancet* 2011; 377: 650–657.
18. O'Byrne PM, FitzGerald M, Bateman ED, et al. Inhaled Budesonide-Formoterol as Needed in Mild Asthma. *N Engl J Med* 2018; 378: 1865–1876.
19. Bateman ED, Reddel HK, O'Byrne PM, et al. Inhaled Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. *N Engl J Med* 2018; 378: 1877–1887.
20. Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. *N Engl J Med* 2019; 380: 2020–2030.
21. Hinds D, Gibbons DC, Gunsoy NB, et al. Eligibility for newer biologic therapies in severe asthma, re-analysis of the IDEAL study. Poster No. 1008 (A5926). ATS International Conference, Dallas, May 17–22, 2019.
22. Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. *Allergy* 2019; DOI: 10.1111/all.13850.